3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Head & Neck
2
Gynecologic
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Hodgkin Disease
36
Lymphoma
34
Lymphoma, Non-Hodgkin
24
Lymphoma, Large B-Cell, Diffuse
24
Lymphoma, Follicular
18
Lymphoma, B-Cell
16
Recurrence
15
Melanoma
14
Neoplasms
12
Mycosis Fungoides
9
Lymphoma, T-Cell
9
Breast Neoplasms
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma, Non-Small-Cell Lung
8
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, T-Cell, Cutaneous
7
Lymphoma, B-Cell, Marginal Zone
7
Head and Neck Neoplasms
7
Sezary Syndrome
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Mantle-Cell
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasm Metastasis
5
Lymphoma, T-Cell, Peripheral
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Interventions
Temozolomide
9
Filgrastim
7
Specimen Handling
6
X-Rays
5
Rituximab
5
Radiotherapy
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Psychiatric Rehabilitation
4
Nuclear Medicine Department, Hospital
4
Methotrexate
4
Etoposide
4
Cyclophosphamide
4
Biopsy
4
etoposide phosphate
3
Pemetrexed
3
Melphalan
3
Cytarabine
3
Carboplatin
3
tazemetostat
2
sargramostim
2
olaparib
2
larotrectinib
2
erdafitinib
2
ensartinib
2
Vincristine
2
Vemurafenib
2
Topotecan
2
Thiotepa
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
pembrolizumab
×
Lymphoid
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled